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THE IMPACT OF HEPARIN 
CONCENTRATION AND 
ACTIVATED CLOTTING TIME 
MONITORING ON BLOOD 
CONSERVATION 
A prospective, randomized 
evaluation in patients 
undergoing cardiac 
operation 
A whole blood hemostasis sYstem (Hepcon) provides both activated clotting 
time and accurate whole blood heparin concentration measurements via an 
automated protamine titration method. This study was designed to pro- 
spectively evaluate the impact of heparin and protamine administration 
using this system on the incidence and treatment of bleeding after 
cardiopulmonary b pass. Two hundred fifty-four patients requiring cardio- 
pulmonary bypass were enrolled in this prospective study over a 7-month 
period. Patients treated with antifibrinolytic agents (aprotinin, r
proic or tranexamic acid) were excluded. Patients were randomly assigned 
to either a control (n = 127) or intervention (n = 127) group. For control 
patients, the anticoagulation protocol consisted of an initial fixed dose of 
250 U/kg of heparin, and additional 5000 U heparin doses were adminis- 
tered if the activated clotting time was less than 480 seconds. Heparin was 
neutralized with an initial fixed dose of protamine (0.8 mg protamine per 
milligram total heparin). For the intervention group, an initial dose of 
heparin was based on an automated heparin dose-response assay. Addi- 
tional heparin doses were administered if the heparin concentration was 
less than the reference concentration or for an activated clotting time less 
than 480 seconds. The protamine dose was based on the residual heparin 
concentration. Treatment of excessive bleeding after cardiopulmonary 
bypass was based on an algorithm using point-of-care testing with whole 
blood prothrombin time, activated partial thromboplastin time, heparinase 
activated clotting time, and platelet count. No differences between the two 
treatment groups were identified in reference to demographic factors, 
preoperative anticoagulant medications, preoperative coagulation data, 
number of reoperations, or combined procedures and duration of cardio- 
pulmonary bypass. Indirect evidence for coagulation factor consumption 
was demonstrated in control patients by more prolonged whole blood 
prothrombin time and activated partial thromboplastin time values after 
cardiopulmonary bypass when compared with values obtained in the 
intervention group. Patients in the intervention cohort received greater 
doses of heparin (intervention: 612 _ 147, controh 462 _ 114 U/kg, p < 
0.0001) and had lower protamine to heparin ratios (intervention: 0.70 - 
0.64, control: 0.94 - 0.21, p = 0.0001) compared with control patients. 
Patients in the intervention cohort received significantly fewer platelet 
(intervention: 1.7 + 3.6 U, control: 3.7 -+ 6.7 U, p = 0.003), plasma 
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(intervention: 0.4 - 1.3 U, control: 1.4 -+ 2.5 U, p = 0.0001), and cryoprecipitate 
units (intervention: 0.0 - 0.0 U, control: 0.2 + 1.2 U, p = 0.04) during the 
perioperative interval than control patients. A greater percentage of control patients 
required hemostatic transfusion (intervention: 17%, control: 33%,p = 0.005) during 
the perioperative period. Control patients also required longer operative times for 
closure (intervention: 92 - 32, control: 102 -+ 34, p = 0.02). Chest tube drainage in 
the first 24 postoperative hours was not different between treatment groups 
(intervention: 839_  + 377, control: 924 - 520, p = 0.14). In summary, mainte- 
nance of patient-specific heparin concentrations, based on heparin activated 
clotting time response, during cardiopulmonary bypass led to greater heparin 
doses and lower doses of protamine relative to heparin dose. Higher porcine 
heparin doses were not associated with excessive postoperative bleeding. By 
facilitating maintenance of a therapeutic heparin concentration and determina- 
tion of an appropriate protamine dose, point-of-care testing using the Hepcon 
system was associated with reduced blood product utilization. This difference 
may, in part, be due to better preservation of the coagulation system. (J THORAC 
CARDIOVASC SURG 1995;110:46-54) 
T he activated clotting time (ACT) is routinely used to assess adequacy of anticoagulation dur- 
ing cardiopulmonary b pass (CPB), to estimate pro- 
tamine dose required to reverse heparin, and to 
evaluate heparin rebound after CPB. Monitoring 
coagulation in the perioperative period exclusively 
with the ACT, however, may be rnisleading inas- 
much as previous studies have demonstrated that 
ACT values during CPB do not correlate well with 
plasma heparin level and are affected by many 
variables uch as hemodilution and hypothermia. ~4 
As previously described, 6-H a whole blood hemosta- 
sis system (Hepcon; Medtronic Hemotec, Engle- 
wood, Colo.) provides both ACT and accurate 
whole blood heparin concentration measurements 
via an automated protamine titration method. 12 
Although data from a retrospective study indicate 
that use of this system can result in reduced iase of 
blood products, a3 another evaluation failed to dem- 
onstrate a difference. 7 This prior, prospective val- 
uation was limited because it did not include an 
adequate number of high-risk patients with pro- 
longed extracorporeal circulation times; in addition, 
a preset heparin level that was independent of each 
patient's heparin anticoagulant response was main- 
tained in all patients. 
Therefore this study was designed tO prospec- 
tively evaluate the impact of heparin and protamine 
administration, as guided by on-site measurements 
of whole blood heparin concentration and ACT, on 
the incidence of bleeding and blood product use 
after CPB. 
Material and methods 
Informed consent was obtained from all patients en- 
rolled in this protocol approved~ by the Institutional 
Human Studies Committee. Exclusion criteria included 
patients requiring emergency procedures, patients treated 
with antifibrinolytic agents (aprotinin, E-aminoeaproic or
tranexamic acid), and patients who had a surgical source 
of bleeding during subsequent exploration. All patients 
were anesthetized with an opioid-based technique; the 
anesthesia was supplemented with inhalational nesthetic 
agents, muscle relaxants, and benzodiazepines, Extracor- 
poreal circulation was accomplished with a Bio-Medicus 
(Medtronics, Minneapolis, Minn.) centripetal pump and a 
Sorin (Sorin Inc., Irvine, Calif.) membrane oxygenator, 
and systemic hypothermia was maintained at 28 ~ C during 
cardioplegia. The CPB system was routinely primed with 
1.5 L of Plasma-Lyte solution, 50 mEq of sodium bicar- 
bonate (NaHCO3) , and 25 gm of mannitol. 
Patients were randomly assigned to either a control (C; 
n = 127) or intervention (I; n = 127) group. For control 
patients, the anticoagulation and reversal protocol con- 
sisted of an initial fixed dose of 250 U/kg of porcine 
heparin, 5000 U added to the CPB circuit, and additional 
5000 U heparin doses administered when the diatoma- 
ceous earth (Celite) ACT was less than 480 seconds. The 
initial protamine dose for control patients consisted of a 
fixed dose of 0.8 mg protamine per milligram total heparin 
administered. For Control patients, adequacy of heparin 
neutralization was based on return of the ACT value to 
the pre-CPB baseline. For patients in the intervention 
group, a heparin dose-response (HDR) assay directed the 
initial dose of heparin and the dose of heparin added to 
the CPB circuit. Additional heparin doses were adminis- 
tered when the heparin concentration was less than the 
initially measured reference concentration or when the 
kaolin ACT was less than 480 seconds. The heparin 
concentration measured after administration of heparin 
and before initiation of CPB that was associated with a 
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Table I. Demographic and operative data 
HC/ACT ACT 
(n = 124) (n = 123) p Value 
Age (yr) 64 + 11 65 • 11 0.32 
Sex (% female) 38 37 0.87 
Weight (kg) 82 • 19 80 _+ 18 0.58 
Body surface area (m 2) 1.93 - 0.23 1.92 • 0.26 0.74 
Operative procedures (%) 
Coronary artery bypass 73 74 0.92 
Arrhythmia operation 3 4 0.75 
Valve repair/replacement 5 9 0.22 
Combined operations 19 13 0.23 
VADS/circulatory arrest (%) 2 2 1.00 
Repeat operations (%) 12 13 0.83 
Preoperative anticoagulation medications (%) 
Aspirin 77 68 0.10 
Heparin 48 39 0.15 
Warfarin 8 7 1.00 
CPB time (min) 145 • 43 144 • 55 0.86 
XC time (min) 77 • 28 77 • 35 0.99 
Values expressed as mean values plus or minus standard eviation or percent. HC/ACT, Intervention cohort using heparin concentration and ACT 
measurements; ACT, control cohort using ACT measurements; combined operations, more than one operative procedure; VADS, ventricular assist devices; 
circulatory arrest, patients who required this technique for thoracic aortic aneurysm repair; XC time, aortic crossclamp time. 
kaolin ACT value of approximately 480 seconds was 
designated as the reference heparin concentration. In the 
intervention group, the initial protamine dose was based 
on the most recent whole blood heparin concentration 
measurement before discontinuation of CPB (1.3 mg of 
protamine per milligram of residual heparin). For inter- 
vention-group atients, adequacy of heparin neutraliza- 
tion was based on a less than 10% difference between 
kaolin ACT and heparinase-treated kaolin ACT values. 
Intraoperative values for ACT or ACT/heparinase ACT 
were obtained 5 minutes after the initial protamine dose 
was given. An additional 50 mg of protamine was admin- 
istered at the discretion of managing physicians with 
administration of blood salvaged in a cell salvage auto 
transfusion instrument (Medtronic Electromedics, Inc., 
Parker, Colo.) or if patients demonstrated evidence of 
excessive bleeding. 
After the patient was rewarmed to 37 ~ C, extracorpo- 
real circulation was discontinued, heparin was neutralized 
with protamine, and patients were observed for excessive 
microvascular bleeding. Excessive microvascular bleeding 
was defined as diffuse bleeding without an identifiable 
surgical source and this diagnosis was made by our 
surgical staff who were unaware of the anticoagulation 
protocol. Treatment of excessive intraoperative bleeding 
after CPB wag standardized by use of a previously de- 
scribed algorithm 14 based on whole blood prothrombin 
time (PT), activated partial thromboplastin time (aPTT), 
and platelet count, which identified quantitative deficien- 
cies of platelets and coagulation factors. Mediastinal chest 
tube drainage during the first 24 postoperative hours was 
recorded hourly; the first recorded value included the 
drainage that occurred intraoperatively after chest closure 
and during the first postoperative hour. Mediastinal chest 
tube drainage designated as excessive by our surgical staff 
during the postoperative period prompted hemostatic 
therapy that was directed by either initially obtained 
laboratory PT, aPTT, and platelet count assays or by 
subsequently obtained whole blood assays. Administra- 
tion of additional protamine in the postoperative period 
was based on whole blood kaolin ACT (heparinase cor- 
rection) or laboratory-based thrombin time assays (prota- 
mine correction), or both methods, for both patient 
groups: 
" Coagulation assays 
Preoperative and postoperative laboratory hematologic 
assays. Laboratory-based hematologic analysis obtained 
preoperatively included complete blood cell count (CBC) 
with platelet count, PT, and aPTT; bleeding times were 
done (Simplate technique) as described by Babson and 15 Babson. On patient arrival in the cardiac intensive care 
unit, laboratory-based hematologic analysis included CBC 
with platelet count, PT, aPTT, and thrombin time with 
protamine correction. In a subset (n = 31) of high-risk 
patients (reoperations or combined procedures) bleeding 
times were done after patient arrival in the intensive care 
unit. A laboratory diagnosis of heparin rebound in the 
post-CPB period was defined with the use of two diagnos- 
tic criteria: (1) an abnormal thrombin time (>18 seconds) 
that corrects (<18 seconds) with protamine and (2) 
patients who meet the first criterion and who also have an 
aPTT value greater than the normal range (>35 seconds). 
On-site, whole blood hematologic assays. Single blood 
specimens obtained either from radial or femoral intraar- 
terial catheters after removal of six dead space volumes or 
from the CPB arterial cannula were used for coagulation 
analysis by on-site, whole blood assays. For control pa- 
tients, anticoagulation and reversal for extracorporeal 
circulation were monitored with diatomaceous earth ACT 
measurements with the Hemochron 801 instrument (In- 
ternational Technidyne, Edison, N.J.). For intervention- 
group patients, anticoagulation a d reversal for extracor- 
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Table II. Hematologic data 
HC/ACT ACT 
(n = 124) (n = 123) p Value 
Preoperative 
Lab PT (sec) 12.9 - 1.5 12.8 + 1.4 0.81 
Lab aPTT (sec) 45.6 _+ 24.2 43.5 + 23.6 0.49 
Lab hematocrit (%) 37.6 -+ 5.6 37.7 + 5.4 0.86 
Lab platelet count (thousands) 241 -+ 80 232 + 63 0.32 
Lab bleeding time (rain) 5.9 • 2.5 6.0 • 3.6 0.82 
Intraoperative 
WB PT (sec) 17.2 • 3.0 18.9 --- 2.9 0.007 
WB aPTT (sec) 48.3 • 13.0 59.4 + 25.6 0.01 
WB hematocrit (%) 24.4 • 5.6 25.0 • 3.3 0.48 
WB platelet count (thousands) 100 - 42 103 --- 39 0.73 
Postoperative 
Lab PT (sec) 15.9 • 1.3 16 -- 1.5 0.72 
Lab aPTT (sec) 28.8 + 5.2 28.8 • 6.8 0.97 
Lab hematocrit (%) 29.6 • 4.3 29.4 -- 4.8 0.82 
Lab platelet count (thousands) 125 + 46 118 • 40 0.20 
Lab thrombin time (sec) 24:7 + 18.3 22.4 -- 10.2 0.22 
Lab PC thrombin time (sec) 18.5 • 3.4 18.9 • 2.7 0.47 
Values expressed as means plus or minus standard eviation. HC/ACT, Intervention cohort using heparin concentration a d ACT measurements; ACT, 
control cohort using ACT measurements; preoperative, during the preoperative p riod; intraoperative, during the intraoperative p riod in a subset of patients 
(n = 101) with evidence of microvascular bleeding; postoperative, during the first postoperative 24 hours; Lab, laboratory; WB, whole blood; WB PT, 
Biotrack-512 whole blood PT, WB aPTT, Biotrack-512 whole blood aPTI'; WB platelet count, whole blood platelet count obtained with a Coulter T540 
hemocytometer; PC thrombin time, protamine-corrected thrombin time in seconds; bleeding time, forearm bleeding time done with a Simplate technique. 
p0real circulation were monitored with whole blood 
heparin and kaolin ACT measurements with the Hepcon 
instrument (Medtronic Hemotec). Adequacy of heparin 
neutralization was assessed with the heparinase ACT 
assay using the ACT instrument (Medtronic Hemotec) for 
intervention-group patients intraoperatively and for all 
patients postoperatively. Whole blood PT, aPTT, and 
platelet count were done on specimens obtained from 
patients with excessive bleeding after CPB to guide spe- 
cific therapy. Whole blood PT and aPTT were determined 
with use of a Biotrack 512 instrument (Boehringer-Mann- 
heim, Indianapolis, Ind.), whereas whole blood CBC with 
platelet counts was measured with either the Coulter T540 
instrument (Coulter Electronics; Hialeah, Fla.) during the 
intraoperative period or the MD series instrument 
(Coulter) during the postoperative period. 
Statistical analysis. Student's unpaired t test was used 
to compare demographic, hematologic, operative interval, 
transfusion, and postoperative blood loss variables that 
were expressed as mean values between treatment groups. 
X z and Fisher's exact analyses were used to compare 
variables that were expressed as percentages between 
treatment groups. 
Results 
Two hundred fifty-four adult patients cheduled 
for cardiac operation requiring CPB were enrolled 
in this study during a 7-month interval. There were 
no differences in demographic oroperative variables 
between the two cohorts (Table I). An equal distri- 
bution (p = 0.68) of patients with a surgical source 
of bleeding at reexploration was evident between 
the control (n = 4) and intervention cohorts (n = 3). 
These seven patients were excluded from the anal- 
ysis. Control patients had significantly greater pro- 
longation in whole blood PT and aPTT values as 
compared with intervention-cohort patients (Table 
II). A trend toward prolonged bleeding times during 
the postoperative period was also evident in control 
patients (C: 8.4 _+ 5.9 minutes, I: 5.9 _+ 3.2 minutes, 
p = 0.12). Otherwise, similar values for laboratory- 
based hematologic assays in both the preoperative 
and postoperative intervals were obtained between 
treatment groups. Intervention-group patients re- 
ceived larger initial and final heparin doses per 
kilogram of weight han control patients (Table III), 
Although the protamine dose per kilogram of 
weight was similar between treatment groups, the 
protamine to heparin ratio was significantly less in 
L 
the intervention cohort. 
Patients treated with both heparin concentration 
and ACT (Hepcon) monitoring received statistically 
fewer platelet, plasma, and cryoprecipitate units 
than control patients (Table IV). Moreover, a 
greater percentage (p = 0.005) of control patients 
(33%) received hemostatic blood product transfu- 
sion as compared with the intervention-cohort pa- 
tients (17%). The operative period after heparin 
neutralization (closure time) was also greater in the 
control patients. 
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Table IIL Heparin anticoagulation, neutralization, and rebound ata 
HC/ACT ACT 
(n - 124) (n = 123) p Value 
Heparin dose 
Initial (UNg) 299 -+ 64 255 -+ 24 <0.0001 
Final (UNg) 612 _+ 147 462 - 114 <0.0001 
Protamine dose (mg/kg) 4.2 _+ 3.6 4.3 + 1.2 0.75 
Protamine:heparin atio 0.70 -+ 0.64 0.94 -+ 0.21 0.0001 
Heparin rebound (%) 
Abnormal thrombin time 34 24 0.10 
Abnormal thrombin time and aPTT 4 2 0.72 
Values expressed as mean values plus or minus standard eviation or percent. HC/ACT, Intervention cohort using heparin concentration and ACT 
measurements; ACT, control cohort using ACT measurements. Heparin dose described at two points: initial refers to the dose administered before 
extracorporeal circulation, whereas final represents the cumulative dose (initial + additional pre-CPB doses + dose administered with CPB). 
Protamine:Heparin ratio refers to the milligram ratio between final protamine and heparin doses. The incidence of heparin rebound was evaluated with 
laboratory-based thrombin time and aPTr assays (see text for complete description). 
The incidence of heparin rebound was similar 
between treatment groups (Table III). Only one 
patient with a laboratory diagnosis (criterion 1) of 
heparin rebound had clinically significant bleeding 
that necessitated a follow-up dose of protamine. 
Control patients had greater mediastinal chest ube 
drainage in the initial postoperative interval (hours 
1 through 4). Although control patients tended to 
have greater mediastinal chest tube drainage in the 
subsequent postoperative intervals, this was not 
statistically significant (Table IV). 
Discussion 
Administration of blood and blood products in 
patients undergoing cardiac operation is being re- 
viewed with intense scrutiny as a consequence of 
increased awareness of the hazards of transfusion- 
related sequelae and cost-containment strategies. 
Consequently, strategies to optimize administration 
of heparin and protamine and the assessment of 
their effects on coagulatio n are undergoing reeval- 
uation in these patients. The impact of heparin/ 
protamine dosing guided by in vitro ACT 13' 16,17 and 
heparin concentration measurements 7' 13 on blood 
conservation has been previously investigated. Re- 
cent data suggest that patients in whom these values 
are monitored with in vitro testing receive more 
heparin, less protamine, and exhibit less postopera- 
tive blood logs.iS The improved clinical outcome in 
this previous trial was ascribed to administration of 
an optimal heparin dose or optimal neutralization of
heparin with protamine, both on the basis of pre- 
dicted in vitro estimates. The present study also 
demonstrates that a coagulation monitoring proto- 
col can minimize blood loss and reduce transfusion 
in patients undergoing cardiac operation. In addi- 
tion to projecting optimal heparin and protamine 
doses, our protocol facilitated maintenance of ther- 
apeutic heparin concentrations during extracorpo- 
real circulation. Patients in our intervention group 
also received more heparin, had a lower protamine 
dose relative to heparin dose, and required fewer 
blood products. Although Gravlee and colleagues 7 
could not demonstrate a clinical advantage when 
heparin concentrations were maintained, our trial 
differed in that it included a significant number of 
patients at risk for bleeding (e.g., long CPB inter- 
vals), the type of heparin used (porcine), and main- 
tainence of patient-specific heparin concentrations. 
The ACT is routinely determined to assess the 
adequacy of anticoagulation before and during CPB, 
Jn the basis of numerous tudies that described a
reduction in postoperative bleeding when the ACT 
was used to monitor heparin therapy. 16' 19, 20 Main- 
tenance of ACT values between 300 and 600 sec- 
onds 21 was initially recommended, because of a 
threefold to sixfold variation in heparin effect and a 
fourfold variation in heparin half-life. 22 Accord- 
ingly, neither total heparin dose nor total time of 
CPB can adequately predict anti-Xa heparin con- 
centrations at the end of CPB. a2 Although there is 
controversy as to what the optimal ACT value for 
CPB is, 5' 23 values between 400 and 480 seconds are 
commonly maintained. The original recommenda- 
tion to maintain a minimum ACT of 300 seconds 
was based on the absence of detectable clots in the 
CPB oxygenator circuit at values higher than this. z4 
Although consumption of clotting factors may be 
minimal for up to 2 hours during CPB if the ACT 
exceeds 400 seconds, 25 ACT-based protocols do not 
suppress thrombin generation during CPB, because 
concentrations of prothrombin fragment 1.2, throm- 
bin/antithrombin complexes, and fibrin monomers 
increase with time during CPB. 26 Recent evalua- 
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Table IV. Blood product use, operative times, and mediastinal chest ube drainage during the perioperative 
interval 
HL/ACT ACT 
(n = 124) (n = 123) p Value 
Blood product use (units) 
Platelet concentrates 1.7 + 3.6 3.7 _+ 6.7 0.003 
Frozen plasma 0.4 _+ 1.3 1.4 _+ 2.5 0.0001 
Cryoprecipitate 0.0 _+ 0.0 0.2 _+ 1.2 0.04 
Red blood cells 1.8 _+ 1.9 2.7 _+ 4.7 0.06 
Closure time (rain) 92 _+ 32 102 _+ 34 0.02 
Chest tube drainage (ml) 
Postop. hours 1-4 255 _+ 136 300 + 215 0.05 
Postop. hours 1-8 406 _+ 209 463 _+ 313 0.09 
Postop. hours 1-24 839 _+ 377 924 _+ 520 0.14 
Values expressed as means plus or minus standard eviation. HC/ACT, Intervention cohort using heparin concentration a d ACT measurements; ACT, 
control cohort using ACT measurements; closure time, time from discontinuation f CPB to the end of the operation; Postop., postoperative, 
tions indicate that duration of CPB is the best 
predictor of microvascular bleeding 14 and blood 
loss 27 after CPB. Patients with tong CPB times have 
lower platelet and coagulation factor levels because 
of a greater degree of consumption. 28 Furthermore, 
judging the adequacy of anticoagulation  the basis 
of the ACT during CPB may be problematic ifias- 
much as numerous tudies have illustrated that ACT 
values during CPB do not correlate with plasma 
heparin concentration. 1-5' 12, 29 This may be a result, 
at least in part, of the influence of CPB-related 
hypothermia nd hemodilution on the ACT as- 
say.i, 3, 12 Other factors that may contribute to in- 
consistent ACT measurements include intrinsic 
variability of ACT measurements during anticoagu- 
lation, along with activation or depression of plate- 
let function. 3~ Therefore ACT-based anticoagula- 
ti0n protocols may contribute to a subclinical 
consumptive state particularly in patients :who re- 
quire prolonged use of CPB (>2 hours). 
Instead, the use of heparin concentration assays 
to maintain a defined heparin level during CPB has 
been recommended by some authors. 6'3~ The Hep- 
con instrument provides both ACT and heparin 
concentration measurements via an automated pro- 
tamine titration method. 6-11 In a recent evaluation, 
good correlations between whole blood heparin 
concentration and anti-Xa plasma heparin concen- 
tration were obtained, indicating that this method 
provides accurate determination f heparin concen- 
tration. 12 In this previous evaluation involving an 
ACT-based anticoagulation protocol in patients in 
whom CPB averaged approximately 21/2 hours, 
plasma equivalent heparin concentration fell below 
previously designated acceptable concentrations (2
U/ml)6, 3o at the end of CPB. In patients with CPB 
times greater than 150 minutes, the decline in heparin 
concentration may reach a subtherapeutic level and, by 
facilitating the consumption of coagulation factors, 
may contribute to excessive bleeding in patients un- 
dergoing cardiac operation. Because generation of 
fibrinopeptide A8'32 and inhibition of clot-bound 
thrombin 33 are inversely related to heparin concentra- 
tion, maintenance of therapeutic heparin levels may 
more effectively preserve coagulation factors by reduc- 
ing activation of the coagulation system through anti- 
thrombin III or possibly heparin cofactor II-mediated 
inactivation of thrombin. 34 Accordingly, patients in the 
control cohort had greater prolongations in whole 
blood PT and aPTT assays after heparin eutralization 
and required more plasma administration. 
In addition, maintenance of a stable heparin 
concentration during extracorporeal circulation may 
preserve platelet function. Although previous tud- 
ies demonstrate that heparin may be a platelet 
agonist,35, 36 recent evaluations have demonstrated a 
consistent dose-related inhibition of collagen-medi- 
ated platelet aggregation by heparin in both in 
vitro 37 and ex vivo 7 models. Higher heparin levels 
during extracorporeal circulation were associated 
with decreased platelet function in the ex vivo 
evaluation. In addition, platelet function is more 
commonly inhibited by heparin, 38 possibly through 
either factor VIII-associated platelet aggregation 39
or through yon Willebrand factor-dependent mech- 
anisms. 4~ In our study, although control patients had 
similar platelet counts after heparin neutralization, 
they also had persistent bleeding that necessitated 
additional transfusion. The trend to more prolonged 
bleeding times in high-risk control patients indicates 
that these patients may have had a more pro- 
nounced qualitative platelet defect. Accordingly, 
5 2 Despotis et al. 
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patients who have increased heparin needs because 
of prolonged use of CPB or preoperative heparin 
infusion may benefit the most from a system that 
guides the maintenance of a therapeutic heparin 
concentration. 
The ACT has been used to estimate protamine 
dose after CPB and to evaluate heparin rebound in 
the postoperative setting. Studies have illustrated 
that reduced doses of protamine for heparin neu- 
tralization after CPB can result in lower periopera- 
tive blood losses. 16-1s Lower perioperative blood 
losses may be a result of reduced complement 
levels41, 42 or reduced protamine-induced platelet 
inhibition 43 associated with lower protamine doses. 
Because Hepcon-derived measurements more reli- 
ably reflect heparin concentration than ACT mea- 
surements, protamine dosing schedules based on 
whole blood heparin measurements facilitated ad- 
ministration of lower protamine doses relative to 
heparin doses. Therefore use of a hemostasis man- 
agement system that evaluates both heparin concen- 
tration and heparin response (ACT) may result in 
the optimal administration of both heparin and 
protamine. 
As previously described in patients who received 
higher heparin doses, postoperative bleeding is not 
increased if patients are monitored for heparin 
rebound in the postoperative period. 7On the basis 
of this finding, we monitored all patients enrolled in 
this project for laboratory and clinical evidence of 
heparin rebound. No evidence of a higher incidence 
of heparin rebound was found in our intervention 
cohort with use of an extremely sensitive laboratory- 
based thrombin time assay (criterion 1) or when we 
evaluated heparin rebound with both thr0mbin time 
and aPTT assays (criterion 2). In addition, the 
incidence of clinically significant heparin rebound 
involving both laboratory (thrombin time) and clin- 
ical criteria (excessive chest tube drainage) was 
extremely low (1 patient of 250 or 0.4%). In contrast 
to recommendations by others, 7 our data do not 
support routine monitoring for heparin rebound in 
the postoperative period when porcine heparin is 
used. However, we would suggest assessment of 
heparin rebound in the setting of clinically signifi- 
cant bleeding before the administration of hemo- 
static blood products. Most important, administra- 
tion of larger heparin doses in our intervention 
cohort was not accompanied by excessive periopera- 
tive bleeding. In fact, less chest tube drainage was 
observed in the intervention-group patients in the 
initial postoperative p riod (hours 1 through 4) and 
a lower percentage of these patients required hemo- 
static therapy for excessive postoperative bleeding. 
In conclusion, our data demonstrate hat mainte- 
nance of reference porcine heparin concentrations 
during CPB results in reduced perioperative use of 
blood products possibly because of preservation 
of the coagulation system. In addition, a lower 
percentage of intervention-group patients who were 
monitored with point-of-care heparin concentration 
testing required hemostatic transfusion. Through facil- 
itated maintenance of a therapeutic heparin concen- 
tration and identification of an accurate protamine 
dose, use of this system can result in reduced use of 
blood products. 
We express appreciation to Cindy Camillo and Amy 
Howe for their invaluable technical support during the 
study and to the cardiac anesthesia and cardiac surgical 
staff for their assistance during this project. 
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